Singapore, Sep 08, 2010: NeoStem, an international biopharmaceutical company with operations in the US and China, has appointed Dr Ian Zhang, as the new President and Managing Director of NeoStem (China).

Dr Zhang is the former Head of Asia Pacific Integration at Life Technologies, where he served on the steering committee managing the acquisition and integration of Applied BioSystems. He is also the former Head of Corporate Development (Asia Pacific) for Invitrogen responsible for growth strategy and acquisitions and integrations, where he had also managed the acquisition and integration of BioAsia, Dynal, Zymed, and Caltech by Invitrogen.

Dr Zhang received his MBA at the University of Chicago, Graduate School of Business and holds a Ph.D. in biotechnology from Simon Fraser University. He continued his education as a postdoctoral fellow at Yale University School of Medicine. His professional focus is on growth strategy and acquisitions/integrations in the biotech field particularly related to biotech growth in Asia.

"Now that we have launched our business in China and are generating revenues, we are excited to add such a seasoned individual to our senior management team to lead the expansion effort," said Dr. Robin Smith, CEO and Chairman of the Board of NeoStem.

Dr Zhang said, "I am excited to join an innovative, forward-looking company like NeoStem and be part of the team of experts to help bring advanced stem cell technologies into China and develop a business in China in a regulatory environment that is supportive of Stem Cells and a healthcare environment that can benefit from technologies to treat diseases using stem cell based therapy."